{"id":3031,"date":"2022-11-27T14:35:38","date_gmt":"2022-11-27T19:35:38","guid":{"rendered":"https:\/\/isologicradiopharm.ca\/premier-radiotraceur-diagnostique-pour-le-diagnostic-precoce-de-la-maladie-dalzheimer-approuve-au-canada\/"},"modified":"2025-05-13T21:27:21","modified_gmt":"2025-05-14T01:27:21","slug":"premier-radiotraceur-diagnostique-pour-le-diagnostic-precoce-de-la-maladie-dalzheimer-approuve-au-canada","status":"publish","type":"post","link":"https:\/\/isologicradiopharm.ca\/en\/premier-radiotraceur-diagnostique-pour-le-diagnostic-precoce-de-la-maladie-dalzheimer-approuve-au-canada\/","title":{"rendered":"First diagnostic radiotracer for early diagnosis of Alzheimer\u2019s disease approved in Canada"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ custom_margin=”0px||||false|false” custom_padding=”0px||||false|false” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ text_text_color=”gcid-primary-color” text_font_size=”16px” text_line_height=”1.9em” background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||||false|false” custom_margin_tablet=”|||-32px|false|false” custom_margin_phone=”|||-32px|false|false” custom_margin_last_edited=”on|phone” hover_enabled=”0″ global_colors_info=”{%22gcid-primary-color%22:%91%22text_text_color%22%93}” theme_builder_area=”post_content” sticky_enabled=”0″]<\/p>\n

\n

PIRAMAL IMAGING SA AND ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS ANNOUNCE COMMERCIAL APPROVAL OF NEURACEQ\u2122 BY HEALTH CANADA<\/span><\/p>\n

Montreal, February 28, 2017 \/CNW Telbec – Piramal Imaging SA and ISOLOGIC Innovative Radiopharmaceuticals today announce that Health Canada has issued a Notice of Compliance (NOC) to ISOLOGIC Innovative Radiopharmaceuticals for NeuraCeq (florbetaben F18 injection). ISOLOGIC has received marketing authorization from Health Canada for the commercial production and market supply of NeuraCeq in Canada. NeuraCeq is the first diagnostic radiotracer to support the early diagnosis of Alzheimer\u2019s disease (AD) that is commercially available in the country. NeuraCeq availability in Canada was previously limited to investigational medicine purposes.<\/span><\/p>\n

\u201cThe commercial availability of NeuraCeq will provide physicians across Canada with a non-invasive method to more confidently and accurately assess complex and atypical cases of patients with cognitive impairment for early diagnosis of Alzheimer\u2019s disease,\u201d said Dr. Jean-Paul Soucy, Medical Director of PET Imaging at the Montreal Neurological Institute. \u201cIn the absence of an approved disease-modifying therapy, improving our ability to make an early and accurate diagnosis of Alzheimer\u2019s disease is critically important to provide optimal symptomatic treatment and non-pharmacological measures to manage disease progression and quality of life for these patients.\u201d<\/span><\/p>\n

NeuraCeq has previously received approval from the FDA and several countries in EU and Asia, and is a diagnostic radiotracer that when used in combination with positron emission tomography (PET) imaging, can identify beta-amyloid plaques in the human brain, which are known as an important biomarker for Alzheimer\u2019s disease.<\/span><\/p>\n

\u201cWe are confident that our commitment to providing access to this new diagnostic beta-amyloid radiotracers in Canada will have a significant impact on the management of patients suspected of having Alzheimer\u2019s disease,\u201d said Andr\u00e9 Gagnon, President and CEO of ISOLOGIC. \u201cIn the context of evidence-based medicine, the introduction of NeuraCeq in the marketplace will offer a new clinical evaluation method for patients, physicians and caregivers alike in the diagnosis and management of Alzheimer\u2019s disease. It could potentially help identify more efficacious interventions to help prevent, halt or slow down this terrible disease.\u201d<\/span><\/p>\n

\u201cWe are very pleased to bring this very important diagnostic imaging tool to new markets like Canada,\u201d said Dr. Ludger Dinkelborg, Director of the Board, Piramal Imaging. \u201cPiramal Imaging is proud to have chosen ISOLOGIC as a partner allowing us to continue our strategic endeavours to provide this important solution to Canadian patients.\u201d<\/span><\/p>\n

About Neuraceq (florbetaben F18 injection)<\/strong><\/h4>\n

Indication<\/strong><\/p>\n

This medicinal product is for diagnostic use only.<\/strong><\/p>\n<\/div>\n

NeuraCeq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease (AD) and other causes of cognitive impairment. NeuraCeq should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no neuritic plaques, which is not consistent with a diagnosis of AD. For the limitations in the interpretation of a positive scan, please refer to the full product monograph.<\/span><\/p>\n

Important Safety Information<\/strong><\/p>\n

NeuraCeq cannot be used to diagnose Alzheimer’s disease and it cannot predict a patient’s predisposition for beta-amyloid neuritic plaques development in the future. NeuraCeq images should only be interpreted by readers trained in the interpretation of PET images with florbetaben F18 injection. Following training, image-reading errors (including false positive or false negative interpretation of NeuraCeq images) may still occur. Additional interpretation errors may occur due to image noise, brain atrophy with a thinned cortical ribbon, or image blurs.<\/span><\/p>\n

Administration of NeuraCeq, as with other radiopharmaceuticals, results in a low amount of ionizing radiation exposure. Safety precautions should be taken to ensure healthcare providers and patients do not receive unintentional radiation exposure from NeuraCeq.<\/span><\/p>\n

Most Common Adverse Events<\/strong><\/p>\n

The most common side effects observed in clinical trials were injection site reaction and injection site pain.\u00a0<\/span><\/p>\n

About Piramal Imaging SA<\/strong><\/h4>\n

Piramal Imaging SA, a division of Piramal Enterprises Ltd., was formed in <span class=”notranslate”>2012<\/span> with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine. Piramal Imaging strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life threatening diseases, leading to better therapeutic outcomes and improved quality of life. For more information please go to www.piramal.com\/imaging.<\/span><\/p>\n

About ISOLOGIC Innovatives Radiopharmaceuticals<\/strong><\/h4>\n

ISOLOGIC Innovative Radiopharmaceuticals (ISOLOGIC) is a Canadian radiopharmaceutical company dedicated to nuclear medicine and the science of radiopharmaceutical production. ISOLOGIC\u2019s commitment to these fields includes cyclotron centers, SPECT and PET radiopharmaceutical manufacturing facilities throughout Canada. Utilizing significant experience, expertise to provide its customers and patients with reliable, safe and high quality radiopharmaceutical products and services. ISOLOGIC\u2019s open formulary of radiopharmaceutical drugs and medical devices provides the flexibility of choice, providing its customers with access to all radiopharmaceuticals, having Health Canada market authorization.<\/span><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

PIRAMAL IMAGING SA AND ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS ANNOUNCE COMMERCIAL APPROVAL OF NEURACEQ\u2122 BY HEALTH CANADA Montreal, February 28, 2017 \/CNW Telbec – Piramal Imaging SA and ISOLOGIC Innovative Radiopharmaceuticals today announce that Health Canada has issued a Notice of Compliance (NOC) to ISOLOGIC Innovative Radiopharmaceuticals for NeuraCeq (florbetaben F18 injection). ISOLOGIC has received marketing authorization […]<\/p>\n","protected":false},"author":1,"featured_media":2893,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[fusion_builder_container admin_label=\"\" hundred_percent=\"no\" equal_height_columns=\"no\" menu_anchor=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"http:\/\/s724396055.online-home.ca\/wp-content\/uploads\/2016\/11\/avada-science-home.jpg\" background_position=\"center center\" background_repeat=\"no-repeat\" fade=\"no\" background_parallax=\"none\" enable_mobile=\"no\" parallax_speed=\"0.3\" video_mp4=\"\" video_webm=\"\" video_ogv=\"\" video_url=\"\" video_aspect_ratio=\"16:9\" video_loop=\"yes\" video_mute=\"yes\" video_preview_image=\"\" border_color=\"\" border_style=\"solid\" margin_top=\"\" margin_bottom=\"\" padding_top=\"150px\" padding_right=\"\" padding_bottom=\"90px\" padding_left=\"\" type=\"legacy\"][fusion_builder_row][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" margin_top=\"\" margin_bottom=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"true\" spacing_right=\"\"][\/fusion_builder_column][fusion_builder_column type=\"2_3\" layout=\"2_3\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"#ffffff\" background_image=\"\" background_position=\"left top\" undefined=\"\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"50px\" padding_right=\"50px\" padding_bottom=\"30px\" padding_left=\"50px\" margin_top=\"\" margin_bottom=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\" spacing_right=\"\"][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

PIRAMAL IMAGING SA ET ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS ANNONCENT L'APPROBATION COMMERCIALE DE NEURACEQ\u2122 PAR SANT\u00c9 CANADA<\/strong><\/h5>\n[\/fusion_text][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"true\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\"][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"true\" spacing_right=\"\"][\/fusion_builder_column][fusion_builder_column type=\"2_3\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\" spacing_right=\"\"][fusion_imageframe image_id=\"769\" style_type=\"none\" stylecolor=\"\" hover_type=\"zoomin\" bordersize=\"\" bordercolor=\"\" borderradius=\"\" align=\"none\" lightbox=\"yes\" gallery_id=\"\" lightbox_image=\"\" alt=\"\" link=\"\" linktarget=\"_self\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]http:\/\/s724396055.online-home.ca\/wp-content\/uploads\/2017\/06\/piramal-pr.jpg[\/fusion_imageframe][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"true\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\"][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"true\" spacing_right=\"\"][\/fusion_builder_column][fusion_builder_column type=\"2_3\" layout=\"2_3\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"#ffffff\" background_image=\"\" background_position=\"left top\" undefined=\"\" background_repeat=\"no-repeat\" border_color=\"#25afb4\" border_style=\"solid\" border_position=\"bottom\" padding_top=\"50px\" padding_right=\"50px\" padding_bottom=\"50px\" padding_left=\"50px\" margin_top=\"\" margin_bottom=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_bottom=\"8\" first=\"false\" spacing_right=\"\"][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

MONTR\u00c9AL, le 28 f\u00e9vr. 2017 \/CNW Telbec<\/h4>\n[\/fusion_text][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n\nPiramal Imaging SA et ISOLOGIC Innovative Radiopharmaceuticals annoncent aujourd'hui que Sant\u00e9 Canada a \u00e9mis un avis de conformit\u00e9 (AC) \u00e0 ISOLOGIC Innovative Radiopharmaceuticals pour NeuraCeq (injection de florbetaben F18). ISOLOGIC a re\u00e7u l'autorisation de mise en march\u00e9 de Sant\u00e9 Canada pour la production commerciale et l'approvisionnement du march\u00e9 de NeuraCeq au Canada. NeuraCeq est le premier radiotraceur de diagnostic \u00e0 soutenir le diagnostic pr\u00e9coce de la maladie d'Alzheimer (MA) disponible dans le commerce dans le pays. La disponibilit\u00e9 de NeuraCeq au Canada \u00e9tait auparavant limit\u00e9e \u00e0 des fins de m\u00e9decine exp\u00e9rimentale.\n\n\u00ab La disponibilit\u00e9 commerciale de NeuraCeq fournira aux m\u00e9decins de partout au Canada une m\u00e9thode non invasive pour \u00e9valuer avec plus de confiance et de pr\u00e9cision les cas complexes et atypiques de patients atteints de troubles cognitifs pour un diagnostic pr\u00e9coce de la maladie d'Alzheimer \u00bb, a d\u00e9clar\u00e9 le docteur Jean-Paul Soucy, directeur m\u00e9dical de l'imagerie TEP. \u00e0 l'Institut neurologique de Montr\u00e9al. \"En l'absence d'un traitement modificateur de la maladie approuv\u00e9, l'am\u00e9lioration de notre capacit\u00e9 \u00e0 poser un diagnostic pr\u00e9coce et pr\u00e9cis de la maladie d'Alzheimer est d'une importance cruciale pour fournir un traitement symptomatique optimal et des mesures non pharmacologiques pour g\u00e9rer la progression de la maladie et la qualit\u00e9 de vie de ces patients.\"\n\nNeuraCeq a d\u00e9j\u00e0 re\u00e7u l'approbation de la FDA et de plusieurs pays de l'UE et d'Asie, et est un radiotraceur de diagnostic qui, lorsqu'il est utilis\u00e9 en combinaison avec l'imagerie par tomographie par \u00e9mission de positrons (TEP), peut identifier les plaques b\u00eata-amylo\u00efdes dans le cerveau humain, qui sont connues sous le nom de un biomarqueur important de la maladie d'Alzheimer.\n\n\u00ab Nous sommes convaincus que notre engagement \u00e0 fournir l'acc\u00e8s \u00e0 ces nouveaux radiotraceurs b\u00eata-amylo\u00efdes diagnostiques au Canada aura un impact significatif sur la prise en charge des patients suspect\u00e9s d'\u00eatre atteints de la maladie d'Alzheimer \u00bb, a d\u00e9clar\u00e9 Andr\u00e9 Gagnon, pr\u00e9sident et chef de la direction d'ISOLOGIC. \u00ab Dans le contexte de la m\u00e9decine factuelle, l'introduction de NeuraCeq sur le march\u00e9 offrira une nouvelle m\u00e9thode d'\u00e9valuation clinique pour les patients, les m\u00e9decins et les soignants dans le diagnostic et la gestion de la maladie d'Alzheimer. Cela pourrait potentiellement aider \u00e0 identifier des interventions plus efficaces pour aider \u00e0 pr\u00e9venir, arr\u00eater ou ralentir cette terrible maladie.\n\n\u00ab Nous sommes tr\u00e8s heureux d'offrir cet outil d'imagerie diagnostique tr\u00e8s important \u00e0 de nouveaux march\u00e9s comme le Canada \u00bb, a d\u00e9clar\u00e9 le Dr Ludger Dinkelborg, directeur du conseil d'administration, Piramal Imaging. \u00ab Piramal Imaging est fi\u00e8re d'avoir choisi ISOLOGIC comme partenaire, ce qui nous permet de poursuivre nos efforts strat\u00e9giques pour fournir cette solution importante aux patients canadiens.\n\n[\/fusion_text][fusion_separator style_type=\"none\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" top_margin=\"40px\" border_size=\"0\" alignment=\"center\" \/][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

\u00c0 propos de Neuraceq (injection de florbetaben F18)<\/h4>\n[\/fusion_text][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n\nIndication<\/strong>\n\nCe m\u00e9dicament est \u00e0 usage diagnostique uniquement.<\/strong>\n\nNeuraCeq est un produit radiopharmaceutique indiqu\u00e9 pour l'imagerie par tomographie par \u00e9mission de positrons (TEP) de la densit\u00e9 de la plaque neuritique b\u00eata-amylo\u00efde dans le cerveau de patients adultes atteints de troubles cognitifs qui sont \u00e9valu\u00e9s pour la maladie d'Alzheimer (MA) et d'autres causes de troubles cognitifs. NeuraCeq doit \u00eatre utilis\u00e9 conjointement avec une \u00e9valuation clinique. Une scintigraphie n\u00e9gative indique des plaques s\u00e9niles clairsem\u00e9es ou inexistantes, ce qui n'est pas compatible avec un diagnostic de MA. Pour conna\u00eetre les limites de l'interpr\u00e9tation d'une scintigraphie positive, veuillez consulter la monographie compl\u00e8te du produit.\n\nInformations importantes sur la s\u00e9curit\u00e9<\/strong>\n\nNeuraCeq ne peut pas \u00eatre utilis\u00e9 pour diagnostiquer la maladie d'Alzheimer et il ne peut pas pr\u00e9dire la pr\u00e9disposition d'un patient au d\u00e9veloppement futur de plaques neuritiques b\u00eata-amylo\u00efdes. Les images NeuraCeq ne doivent \u00eatre interpr\u00e9t\u00e9es que par des lecteurs form\u00e9s \u00e0 l'interpr\u00e9tation d'images TEP avec injection de florbetaben F18. Apr\u00e8s la formation, des erreurs de lecture d'images (y compris l'interpr\u00e9tation faussement positive ou faussement n\u00e9gative des images NeuraCeq) peuvent encore se produire. Des erreurs d'interpr\u00e9tation suppl\u00e9mentaires peuvent survenir en raison du bruit de l'image, de l'atrophie c\u00e9r\u00e9brale avec un ruban cortical aminci ou des images floues.\n\nL'administration de NeuraCeq, comme d'autres produits radiopharmaceutiques, entra\u00eene une faible exposition aux rayonnements ionisants. Des pr\u00e9cautions de s\u00e9curit\u00e9 doivent \u00eatre prises pour s'assurer que les prestataires de soins de sant\u00e9 et les patients ne re\u00e7oivent pas d'exposition involontaire aux rayonnements de NeuraCeq.\n\n\u00c9v\u00e9nements ind\u00e9sirables les plus courants<\/strong>\n\nLes effets ind\u00e9sirables les plus fr\u00e9quemment observ\u00e9s dans les essais cliniques \u00e9taient la r\u00e9action au site d'injection et la douleur au site d'injection.\n\n[\/fusion_text][fusion_separator style_type=\"none\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" top_margin=\"40px\" border_size=\"0\" alignment=\"center\" \/][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

\u00c0 propos de Piramal Imaging SA<\/h4>\n[\/fusion_text][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n\nPiramal Imaging SA, une division de Piramal Enterprises Ltd., a \u00e9t\u00e9 cr\u00e9\u00e9e en 2012 avec l'acquisition du portefeuille de recherche et d\u00e9veloppement en imagerie mol\u00e9culaire de Bayer Pharma AG. En d\u00e9veloppant de nouveaux traceurs TEP pour l'imagerie mol\u00e9culaire, Piramal Imaging se concentre sur un domaine cl\u00e9 de la m\u00e9decine moderne. Piramal Imaging s'efforce d'\u00eatre un leader dans le domaine de l'imagerie mol\u00e9culaire en d\u00e9veloppant des produits innovants qui am\u00e9liorent la d\u00e9tection pr\u00e9coce et la caract\u00e9risation des maladies chroniques et potentiellement mortelles, conduisant \u00e0 de meilleurs r\u00e9sultats th\u00e9rapeutiques et \u00e0 une meilleure qualit\u00e9 de vie. Pour plus d'informations, rendez-vous sur www.piramal.com\/imaging.\n\n[\/fusion_text][fusion_separator style_type=\"none\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" top_margin=\"40px\" border_size=\"0\" alignment=\"center\" \/][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

\u00c0 propos d'ISOLOGIC Innovatives Radiopharmaceutiques<\/h4>\n[\/fusion_text][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n\nISOLOGIC Innovative Radiopharmaceuticals (ISOLOGIC) est une soci\u00e9t\u00e9 radiopharmaceutique canadienne d\u00e9di\u00e9e \u00e0 la m\u00e9decine nucl\u00e9aire et \u00e0 la science de la production radiopharmaceutique. L'engagement d'ISOLOGIC dans ces domaines comprend des centres de cyclotrons, des installations de fabrication de produits radiopharmaceutiques SPECT et PET \u00e0 travers le Canada. Utilisant une exp\u00e9rience et une expertise significatives pour fournir \u00e0 ses clients et patients des produits et services radiopharmaceutiques fiables, s\u00fbrs et de haute qualit\u00e9. Le formulaire ouvert de m\u00e9dicaments radiopharmaceutiques et d'instruments m\u00e9dicaux d'ISOLOGIC offre une flexibilit\u00e9 de choix, offrant \u00e0 ses clients un acc\u00e8s \u00e0 tous les produits radiopharmaceutiques ayant une autorisation de mise en march\u00e9 de Sant\u00e9 Canada.\n\n[\/fusion_text][fusion_sharing tagline=\"Share this post\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" \/][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"true\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\"][\/fusion_builder_column][\/fusion_builder_row][\/fusion_builder_container]","_et_gb_content_width":"","footnotes":""},"categories":[16],"tags":[],"class_list":["post-3031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dans-la-presse"],"_links":{"self":[{"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/posts\/3031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/comments?post=3031"}],"version-history":[{"count":0,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/posts\/3031\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/media\/2893"}],"wp:attachment":[{"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/media?parent=3031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/categories?post=3031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/tags?post=3031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}